Can I Take Ashwagandha with Addyi (Flibanserin)?

What Is Flibanserin (Addyi) and How Does It Work?

Flibanserin is the only FDA-approved non-hormonal medication for hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts as a serotonin 1A receptor agonist and a serotonin 2A receptor antagonist, with weaker dopamine D4 agonism. The FDA approved it in August 2015 after two prior rejections, largely because a third submission included stricter alcohol-interaction data. [1]

Metabolism and the CYP3A4 Connection

Flibanserin is primarily metabolized by CYP3A4, with minor contributions from CYP2C19 and CYP1A2. [2] That metabolic route matters enormously for supplement interactions. The prescribing label states that co-administration with moderate or strong CYP3A4 inhibitors is contraindicated because plasma flibanserin concentrations rise sharply, magnifying both hypotension risk and CNS depression. [2]

Ashwagandha's withanolides, specifically withaferin A, have demonstrated CYP3A4 inhibitory activity in vitro. [3] The inhibition potency is classified as moderate in most pharmacognosy analyses, which places it in the same regulatory tier as fluconazole. Moderate CYP3A4 inhibition of flibanserin increased its AUC 2-fold in the label's pharmacokinetic studies. [2]

The Bedtime Dosing Problem

Flibanserin must be taken at bedtime specifically to reduce daytime hypotension and syncope risk. Ashwagandha taken on the same schedule for sleep support compounds sedation at the exact moment the drug's CNS-depressant peak occurs. Studies of KSM-66 ashwagandha 300 mg twice daily over 10 weeks showed a statistically significant improvement in sleep quality scores, confirming a genuine sedative pharmacodynamic effect at standard doses. [4]

What Does Ashwagandha Actually Do Pharmacologically?

Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen with at least three pharmacological axes relevant to someone taking flibanserin: enzyme inhibition, cortisol suppression, and thyroid hormone modulation. [5]

CYP3A4 Inhibition by Withanolides

Withaferin A and withanone, two steroidal lactones concentrated in ashwagandha root, inhibit CYP3A4-mediated metabolism in human liver microsome assays. [3] A 2021 in-vitro study published in Phytomedicine reported an IC50 for withaferin A against CYP3A4 of approximately 6.8 micromolar. [3] Clinical confirmation of this effect in healthy volunteers taking commercial ashwagandha extracts is still sparse, but the mechanistic signal is consistent enough that the Natural Medicines Comprehensive Database flags the combination as "use with caution." [6]

Cortisol Reduction and HPA Axis Effects

In a double-blind RCT (N=64) published in Medicine (Baltimore), participants randomized to 300 mg twice daily of ashwagandha root extract for 60 days showed a 27.9% reduction in serum cortisol versus a 7.9% reduction in the placebo group (P<0.001). [7] Chronic cortisol elevation is independently associated with reduced sexual desire in premenopausal women, so cortisol lowering is one proposed mechanism by which ashwagandha might support libido on its own. [8]

That same cortisol reduction, however, can cause orthostatic blood-pressure variability. Flibanserin already depresses blood pressure through central sympatholysis; layering a cortisol-modulating agent on top of that creates an additive hemodynamic risk profile. [2]

Thyroid Hormone Elevation

A randomized, double-blind, placebo-controlled trial (N=50) published in the Journal of Alternative and Complementary Medicine found that 600 mg/day of ashwagandha root extract for 8 weeks significantly increased serum T4 by 19.6% and serum T3 by 41.5% compared to placebo. [9] Thyroid hormones influence serotonin receptor density and dopaminergic tone. Both pathways are directly engaged by flibanserin's mechanism of action. [10]

Subclinical hyperthyroidism from supplement-driven T3 elevation could theoretically reduce flibanserin efficacy by downregulating the very serotonin 1A receptors the drug depends on, though prospective clinical data on this specific interaction remain absent. [9]

Pharmacokinetic Interaction: How Significant Is the CYP3A4 Overlap?

The flibanserin label's PK section quantifies this risk clearly. Co-administration with fluconazole (a moderate CYP3A4/CYP2C19 inhibitor) raised flibanserin AUC by approximately 7-fold and Cmax by 2-fold. [2] Fluconazole is the closest labeled comparator to ashwagandha's inhibitory profile.

What a 2-Fold AUC Increase Means Clinically

A 2-fold increase in flibanserin exposure roughly doubles the probability of reaching plasma concentrations associated with hypotension and syncope events. In the VIOLET trial, hypotension and syncope occurred in 0.4% of patients on flibanserin alone versus 4.1% when a CNS depressant (alcohol) was co-administered. [11] The proportional risk increase from a moderate CYP3A4 inhibitor would not match the alcohol data exactly, but the directional signal is the same: elevated drug levels produce more adverse cardiovascular events.

P-glycoprotein Interactions

Ashwagandha may also inhibit P-glycoprotein (P-gp) efflux pumps. [3] Flibanserin is a P-gp substrate. P-gp inhibition independently raises drug bioavailability by reducing first-pass intestinal efflux, compounding any CYP3A4-based exposure increase. The additive effect of simultaneous CYP3A4 and P-gp inhibition has not been studied for this combination but is a documented concern with other steroidal botanical compounds. [12]

Pharmacodynamic Interaction: CNS Depression and Blood Pressure

Flibanserin's black-box warning explicitly names CNS depressants as contraindicated co-medications during the same evening. [2] Ashwagandha's sedative and anxiolytic effects are well-documented and mechanistically rooted in GABA-A receptor potentiation by withanolides. [13]

GABA-A Agonism and Additive Sedation

A 2021 study in PLOS ONE demonstrated that withanolide glycosides bind to GABA-A receptor chloride channels with affinity comparable to low-dose benzodiazepines. [13] Taking ashwagandha at bedtime alongside flibanserin therefore mimics the scenario the black-box warning was designed to prevent, even though the supplement is not specifically named on the label.

Orthostatic Hypotension Risk

In the FDA's safety review that preceded approval, orthostatic hypotension was recorded in 0.2% of patients in controlled trials and in higher proportions in post-marketing surveillance data. [1] Cortisol suppression by ashwagandha can independently lower blood pressure, particularly upon standing. [7] Women who already experience dizziness on flibanserin alone should treat any additional cortisol-lowering supplement as a relevant hemodynamic variable.

Does Ashwagandha Actually Help HSDD on Its Own?

This question matters because some women add ashwagandha specifically to boost libido, sometimes as a stepping stone before starting Addyi or as an adjunct. The evidence is real but narrow.

The KSM-66 Female Sexual Function Data

A double-blind, randomized, placebo-controlled trial published in BioMed Research International (N=50 women, 8 weeks, 300 mg KSM-66 twice daily) found statistically significant improvements in Female Sexual Function Index (FSFI) total score, specifically in domains of desire, arousal, lubrication, and orgasm. The placebo-corrected effect was meaningful across all measured domains (P<0.001 for total score). [14] The proposed mechanisms include cortisol reduction, testosterone support, and reduced psychogenic anxiety. [14]

Testosterone Modulation

Ashwagandha raised total testosterone by a mean of 14.7% versus placebo in a 2019 RCT in healthy men (N=43). [15] Female sexual desire correlates modestly but consistently with free testosterone, and several HSDD treatment guidelines acknowledge androgen insufficiency as a contributing factor. [16] Whether the testosterone effect in women is comparable in magnitude to what was observed in men has not been confirmed in an adequately powered female-specific trial.

Clinical Decision Framework: Should You Combine Them?

No single published clinical trial has tested ashwagandha plus flibanserin as a co-regimen. The evidence base requires synthesizing separate pharmacology streams.

Risk Stratification by Patient Profile

Lower combined risk applies to women who take ashwagandha in the morning (creating a 10-to-12-hour separation from bedtime flibanserin), use doses at or below 300 mg/day of a standardized root extract, have normal baseline thyroid function confirmed by TSH assay, and have no history of orthostatic hypotension or syncope on flibanserin alone.

Higher combined risk applies to women who take ashwagandha in the evening or near bedtime, use doses above 600 mg/day, have pre-existing thyroid disease or are on levothyroxine, already experience dizziness on flibanserin, or take other CYP3A4 inhibitors (e.g., itraconazole, ketoconazole) concurrently.

Timing Strategy if a Prescriber Approves the Combination

The pharmacokinetic half-life of flibanserin is approximately 11 hours. [2] Taking ashwagandha in the morning minimizes the temporal overlap with peak flibanserin plasma concentrations, which occur approximately 45 minutes after bedtime dosing. [2] A 10-to-12-hour offset does not eliminate CYP3A4 overlap entirely because withanolide concentrations persist longer than their serum peak, but it substantially reduces the simultaneous-inhibition risk window.

Laboratory Monitoring Recommendations

Women who use both agents should have a baseline TSH and free T4 drawn before starting ashwagandha and again at 8 to 12 weeks. A 2019 systematic review in the Journal of Ethnopharmacology documented thyroid-stimulating effects in three of four included RCTs, making TSH surveillance clinically justified rather than precautionary. [17] Blood pressure should be checked at home with a validated cuff device for the first two weeks of combined use, particularly after the bedtime dose.

What the FDA Label Says About Drug Interactions

The Addyi prescribing information, last updated March 2019, lists the following as contraindicated co-administrations: strong and moderate CYP3A4 inhibitors, CNS depressants, and alcohol. [2] Botanical supplements are not individually named, but the label contains the explicit warning: "Other drugs that inhibit CYP3A4 may also increase flibanserin exposure and the risk of hypotension, syncope, and CNS depression." [2]

The Endocrine Society's clinical practice guideline on female sexual dysfunction acknowledges that "the magnitude of benefit of flibanserin over placebo is modest" and calls for careful attention to drug interactions before prescribing. [18] The guideline does not address ashwagandha specifically, reflecting how recently herbal-drug interaction research has emerged as a clinical discipline.

What to Do If You Are Already Taking Both

Stop taking ashwagandha at the same time as your flibanserin dose immediately. Contact your prescribing clinician to review your current regimen. Bring the specific ashwagandha product to your appointment or photograph the label, because dose per capsule varies substantially between brands. Request a TSH and blood pressure review at the visit.

If you have experienced dizziness, near-fainting, or unusual fatigue since combining the two agents, treat this as an urgent rather than routine call to your prescriber. [2] Post-marketing flibanserin adverse event reports to the FDA have included syncope outside the controlled trial setting, and unreported supplement co-use may be a contributing variable in some of those cases. [1]